Immunotherapies for CancerOxford BioTherapeutics (OBT) is a clinical stage oncology company focussed only on first-in-class immune therapies, with special emphasis on improving outcomes for patients with solid tumors who respond poorly to PD-1 inhibitors. Our lead asset, OBT076, is an Antibody Drug Conjugate (ADC) in Phase 1b clinical development. OBT076's dual mechanism of action allows it to act as a 'primer' to re-engage the patient's immune system while at the same time targeting cancer cells directly. Our clinical and pre-clinical pipeline of novel immunotherapies is balanced between internal programs, focused on ADCs and checkpoint regulators, and externally partnered programs with key innovators in oncology such as Boehringer Ingelheim and Kite, a Gilead company. Our OGAP® platform is the world's largest, cancer specific, membrane protein library, directly measuring plasma membrane protein expression in patient tumors. OGAP is used to identify novel, highly tumor specific antigens for novel first-in-class ADC, Bispecific T-cell Engager (BITE®) and Chimeric Antigen Receptor (CAR) targets. |
|
© 2017 Oxford BioTherapeutics All Rights Reserved